Breaking AI & Tech News Analyzed

Doctors Without Borders (MSF) has condemned a drone strike that hit Al Jabalain Hospital in Sudan’s White Nile State, killing 10 people, among them seven medical staff members. The attack, which struck an operating theatre and a maternity ward, occurred during a children’s immunisation campaign, heightening the humanitarian outcry.MSF’s Sudan emergencies chief, Esperanza Santos, said the assault was “unacceptable” and noted that several of the deceased had previously worked with the organisation. She added that the strike represents a grave violation of medical neutrality.While the perpetrators have not been officially confirmed, MSF’s statement attributes the strike to the paramilitary Rapid Support Forces (RSF), a claim echoed by Sudanese officials. On Friday, Khalid Aleisir, Sudan’s minister of culture, information, antiquities and tourism, called for the RSF to be designated a terrorist organisation and for its members to face prosecution.The incident follows a series of attacks on Sudan’s health infrastructure since the war erupted in April 2023. In a separate incident the same day, a medical supply depot in Rabak, the capital of White Nile State, was also hit. According to the World Health Organization, more than 200 attacks have targeted health facilities since the conflict began, underscoring a systematic pattern of violence against civilians.Local rights group Emergency Lawyers highlighted that recurring drone strikes across South Kordofan, Blue Nile, and the Darfur regions have displaced thousands, further straining an already fragile health system. The Sudan Doctors Network described the Al Jabalain strike as a “deliberate assault on health facilities and unarmed civilians,” warning that such actions exacerbate the nation’s deteriorating medical capacity.International observers note that the targeting of hospitals not only violates international humanitarian law but also hampers efforts to control disease outbreaks and provide essential care to vulnerable populations. The growing body of evidence may prompt renewed calls for accountability and stronger protective measures for health workers in conflict zones.

The World Health Organisation (WHO) has issued a stern warning against the ongoing US-Israeli attacks on Iranian healthcare facilities, amid the escalating conflict. The organisation's chief, Tedros Adhanom Ghebreyesus, reported that over 20 attacks on healthcare facilities in Iran have been verified since March 1, resulting in at least nine deaths, including an infectious diseases health worker and a member of the Iranian Red Crescent Society.The Pasteur Institute in Tehran, one of the oldest research and health facilities in the country, has sustained significant damage and was rendered unable to continue delivering health services. Iranian Ministry of Health spokesperson Hossein Kermanpour shared images of the heavily damaged building on social media, with parts of the facility reduced to rubble.Despite the attacks, Iran's ISNA news agency reported that the services of the Pasteur Institute have not been interrupted, and vaccine and serum production would continue. The WHO chief emphasised that the Institute plays a crucial role in protecting and promoting population health, particularly in emergencies.The attacks have not been limited to the Pasteur Institute. The WHO has reported damage to other healthcare facilities, including the Delaram Sina Psychiatric Hospital and the Tofigh Daru pharmaceutical facility, with no casualties reported. An explosion near the Imam Ali Hospital in Khuzestan province led to the facility's evacuation and cessation of services.Tedros stressed that humanitarian workers, ambulances, relief supplies, and humanitarian facilities must be respected and protected under international law. The Geneva Conventions, agreed upon after World War II, designate healthcare facilities as protected locations.The Iranian Red Crescent Society reported that a warehouse belonging to the organisation was targeted, destroying two-wheeled relief containers and two buses and relief vehicles. According to the organisation, 307 health, medical, and emergency care facilities have been damaged in the war.

On a sun‑lit picnic beside Canberra’s Molonglo River, a tartan blanket, a bottle of wine, crusty baguette, cheese and a daring chicken‑and‑grape salad from a gourmet magazine marked the beginning of a romance that would be defined by food.Their shared appetite for culinary experimentation quickly turned into a series of kitchen showdowns—debates over meat doneness, oven temperatures, seasoning ratios and the eternal butter‑vs‑oil dilemma. While the clashes were frequent, the meals they produced together often became celebrated triumphs.Over the years, their lives were chronicled in the spines of recipe books and the aromas of countless dinners. From the quest for the perfect loaf to the fiery sting of chilies that left a lasting impression, each dish mapped the highs and lows of their partnership.He gravitated toward savoury mains; she honed a talent for desserts. Their culinary quirks—her habit of returning leftovers to the fridge, his ritual of swaddling roasted meat in tea towels—added both friction and flavor to their shared table.Even after their separation, the couple’s kitchen remains a shared space. A well‑worn ceramic baking tray, scarred by years of roasting turkeys, chickens and lamb, still serves as the foundation for gravy‑making and other culinary rituals during holiday gatherings.One of his most enduring contributions is a dish they call Pasta Dimanche. Born from a pantry raid on a Sunday night, the pasta blends diced capsicum, carrot, purple onion, garlic, celery, parsley and tomato with a tin of tuna, cracked pepper, salt and a splash of Tabasco and green chilli sauce. The result is a vibrant, summery plate that celebrates colour, texture and the surprise harmony of warm and crisp.Recipe: Pasta Dimanche (Serves 4)Ingredients:1 red onion, finely chopped1 carrot, finely diced3 garlic cloves, finely chopped1 yellow capsicum, finely chopped1 green capsicum, finely chopped1 red capsicum, finely chopped1 cup finely chopped parsley370 g tin tuna, drained1 tsp Tabasco1 tsp green TabascoDried pasta of choice (to serve)Method:1. Toss the vegetables, garlic, parsley and tuna in a large bowl; season with Tabasco, salt and pepper.2. Cook pasta in salted boiling water until al dente; drain.3. Divide pasta among four bowls, top with the tuna‑vegetable mix, and serve.Despite their split, they continue to exchange food news, recipe links from the New York Times, and tips on premium ingredients—proving that a shared love of cooking can outlast even the most intimate of relationships.

As Easter celebrations unfold in the UK, religious and political leaders are highlighting the urgent need for peace in the Middle East, a region plagued by conflict and violence. The Archbishop of Canterbury, Dame Sarah Mullally, in her first Easter sermon, called for an end to the violence and destruction in the region, emphasizing the importance of “peace, justice, and freedom.”The conflict in the Middle East, which began at the end of February, has entered its sixth week, resulting in thousands of deaths and significant disruptions to global shipping routes, including an effective blockade of the Strait of Hormuz. This has led to soaring fuel prices and concerns about the impact on the global economy.In her Easter message, Mullally prayed that all people in the region receive the peace, justice, and freedom they long for, stating, “This week, our gaze and our prayers have been turned towards the land where Jesus was crucified and raised from the dead. Today, as we shout with joy that Christ is risen, let us pray and call with renewed urgency for an end to the violence and destruction in the Middle East and the Gulf.”Prime Minister Keir Starmer also addressed the conflict in his Easter message, noting that it is causing “real anxiety” for people. He described Easter as a celebration of hope, new life, and renewal, and highlighted the important role of churches and Christian communities in supporting families and neighbors.Starmer emphasized the need for unity and community in the face of challenges, stating, “Our country is at its best when we choose community over division, kindness over indifference, and service over self-interest.”

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

TGI Fridays, a global bar-restaurant chain, is set for a UK revival under the leadership of Ray Blanchette, who has acquired the brand's UK arm. Blanchette, a former TGI Fridays kitchen manager, believes the chain can regain its momentum in the UK and expand globally to 1,000 outlets. The UK restaurant industry has faced significant challenges, including higher staffing, energy, and food costs, as well as decreased diner numbers due to financial constraints. However, Blanchette is optimistic about TGI Fridays' prospects, citing its rich history and legacy as a foundation for growth. Blanchette's investment firm, Sugarloaf, has taken control of the global master franchise for TGI Fridays and directly operates 11 US outlets and the UK restaurants. He plans to invest over £2.5m in revamping restaurants, updating kitchen equipment, and enhancing staff training. Blanchette acknowledges that the UK tax regime for high street businesses is 'problematic' and stifles growth. He hopes for government change, given hospitality's significant role as one of the UK's largest employers. The revamped TGI Fridays UK will focus on providing an 'over the top and fun' experience, with a new menu, affordable options, and improved service. Blanchette is confident that a turnaround is possible, having read hundreds of thousands of online reviews of the UK business.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

As the 2026 local and regional elections draw nearer, the spectre of Trussonomics looms large over the British political landscape. From the Conservatives to the Greens, parties are unveiling extravagant fiscal promises that they claim can be funded by cuts elsewhere or additional borrowing, while insisting the broader economy will remain unharmed. Critics warn that any adverse effects will inevitably be shifted onto people and businesses outside the parties' core constituencies, effectively socialising the risk. Only Keir Starmer and his Labour cabinet appear to resist the pressure to re‑engineer the economy without acknowledging inevitable spill‑overs or extra costs. Former Prime Minister Liz Truss famously pledged £45 bn of tax cuts, financed through extra borrowing and so‑called welfare “efficiencies”. The plan was pitched as a catalyst for an entrepreneurial surge that would lift the UK out of a prolonged period of low productivity. Heading into May’s local polls, the Conservatives are touting a new “big‑spending” agenda after recent welfare cuts, highlighted by a headline pledge to shrink the welfare bill by £23 bn. Shadow Chancellor Mel Stride declared that the “culture of ‘something for nothing’ must end, now”. Green Party leader Zack Polanski has softened some of his party’s more radical proposals, yet the manifesto remains vague. Earlier drafts featured a litany of “free lunches”, signalling an ambition to raise taxes by **more than £170 bn a year** by the end of the next parliament. Key components of the Green plan include a £90 bn annual carbon tax and a matching increase in day‑to‑day public spending, alongside a proposed £90 bn boost to the capital‑spending budget (raising it from £160 bn to £250 bn per year). Reform UK has embraced Trussonomics with gusto, promising to raise the income‑tax threshold from £12,570 to £20,000 – a move that would cost the exchequer **over £40 bn each year**. Underlying many of these pledges is a belief that the UK can reverse a century of economic decline with a “magician’s wand”, ignoring potential repercussions for financial markets, trading partners, and a rapidly disintegrating global order. While the article briefly references the United States and France, the French electorate’s recent rejection of similarly flamboyant policies in local elections serves as a cautionary tale: voters in key cities like Paris and Marseille opted for centrist candidates over the radical platforms of Marine Le Pen’s National Rally and Jean‑Luc Mélenchon’s LFI. The broader context is a decade marked by two major wars, a quantum technological shift, and accelerating climate change – none of which offer quick‑fix solutions. Labour’s economic strategy, championed by Rachel Reeves, hinges on an early‑parliament spending surge intended to generate growth before the next general election. However, the damage inflicted by the previous government is still being reassessed, with the public‑finance gap now appearing larger than the £22 bn initially highlighted by Reeves. Labour still holds considerable funds earmarked for investment, but bureaucratic inertia in Whitehall hampers swift action, and Starmer bears responsibility for this paralysis. Demonstrating tangible returns on public spending – with HS2 currently the sole benchmark – could justify future tax increases on higher earners, provided the money is not wasted. In an uncertain world, the article argues that rational, evidence‑based governance is preferable to “outlandish initiatives” that create a multitude of losers. Ultimately, the piece concludes that Truss’s experiment was a disaster not merely because of the misguided belief that tax cuts can drive sustainable growth in a mature economy, but because it relied on an imagined “escape hatch” to propel the UK to a higher economic plane.

The UK is facing a potential rebranding of its beloved breakfast spread, marmalade, due to new EU rules. The proposed changes are part of a planned food deal with the EU, which would require the UK to align with the bloc's naming rules for food products.Under the new rules, marmalades may need to be relabelled to specify the type of fruit used, such as 'citrus marmalade'. However, the government has clarified that 'orange marmalade' will still be allowed and that jars on UK shelves will remain unchanged.The Conservative former home secretary, Priti Patel, has accused Labour of 'attacking the great British marmalade', claiming that the prime minister is 'desperate to fit in with his EU pals and unpick Brexit'. However, the government spokesperson has denied this, stating that the deal simply supports trade by cutting unnecessary red tape.The UK is being asked to align with regulations already in force within the EU, which allow all conserves to be marketed as marmalades as long as the type of fruit is specified. The rules were relaxed in 2004 to allow fruit-based spreads to be referred to as marmalades in certain European countries.A government source pointed out that marmalade on UK supermarket shelves is already usually labelled as 'orange marmalade', which they suggested is in compliance with the EU rules. The government has assured that the agreement supports exporters while fully preserving the UK's ability to shape food rules in the national interest.